CN Patent

CN113209000B — 用于药物递送和保护眼睛前段的眼用制剂

Assigned to Panoptica Inc · Expires 2025-05-13 · 1y expired

What this patent protects

本申请涉及局部制剂，其包含化合物‑I 或其游离碱，和选自烟酸、烟酰胺和维生素K及其组合的第二活性剂，其用于治疗眼部新生血管形成。本申请还涉及包含化合物‑I或其游离碱的颗粒的药物组合物和包含化合物‑I或其游离碱的颗粒组合物的混悬液制剂。

USPTO Abstract

本申请涉及局部制剂，其包含化合物‑I 或其游离碱，和选自烟酸、烟酰胺和维生素K及其组合的第二活性剂，其用于治疗眼部新生血管形成。本申请还涉及包含化合物‑I或其游离碱的颗粒的药物组合物和包含化合物‑I或其游离碱的颗粒组合物的混悬液制剂。

Drugs covered by this patent

triamcinolone-acetonide (TRIAMCINOLONE ACETONIDE)

Patent Metadata

Patent number: CN113209000B
Jurisdiction: CN
Classification: —
Expires: 2025-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Panoptica Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.